Healthcare,Healthcare sector projects by Piramal Enterprises Limited in
Project Information
5162
Piramal Enterprises Limited
Piramal Enterprises Limited has received approval from the US FDA for its Investigational New Drug (IND) P7435, for treatment of metabolical disorders. P7435 has been developed by the NCE Research Division of PEL for the management of metabolic disorders such as lipid abnormalities and diabetes. It is well-established that an increased lipid level (including triglycerides) is one of the major risk factors for cardiovascular disease (CVD). Piramal Enterprises has established the safety and tolerability of ''P7435'' in a phase I trial recently completed in India. It is now planning to initiate extended phase I trial in the US to further evaluate the safety and efficacy of the new chemical entity in a larger population. Piramal Enterprises Vice Chairperson Swati Piramal said: "Expansion of this trial will allow testing this NCE in a wider population, which is critical to the development of this drug and will provide therapeutic solutions not just to India but also to the rest of the world. The company''s R&D division has been focusing on discovery and development of medicines to target disease such as cancer, metabolic disorders and inflammatory conditions.
Project Value
Refer document
Pre Project Activities Underway
Not Specified
India
Healthcare,Healthcare
Disclaimer :
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.
